Health ❯ Healthcare ❯ Pharmacology

Monoclonal Antibodies

Mechanism of Action Benralizumab Cetuximab Zigakibart Nirsevimab CD20+ B Cells Ocrelizumab INCA033989 BAFF Pathway

Ianalumab Plus Eltrombopag Extends Disease Control in Phase 3 ITP Study Published in NEJM

Peer‑reviewed results point to a finite, disease‑modifying strategy for previously treated patients, with regulatory decisions still ahead.

FDA Grants Breakthrough Therapy Designation to Incyte’s CALR‑Targeting Antibody as ASH Data Show Early Efficacy in Myelofibrosis

Ocrelizumab Outperforms Rivals on MS Relapse Control in Real-World Study

Zigakibart sustains proteinuria remission and stabilizes kidney function over 100-week IgA nephropathy trial

Single Dose of Nirsevimab Halves Bronchiolitis Admissions in Infants Under Six Months

Avelumab and Cetuximab Combo Quadruples Progression-Free Survival in Advanced cSCC